141 related articles for article (PubMed ID: 1318682)
1. Study of the parameters of binding of R 61837 to human rhinovirus 9 and immunobiochemical evidence of capsid-stabilizing activity of the compound.
Moeremans M; De Raeymaeker M; Daneels G; De Brabander M; Aerts F; Janssen C; Andries K
Antimicrob Agents Chemother; 1992 Feb; 36(2):417-24. PubMed ID: 1318682
[TBL] [Abstract][Full Text] [Related]
2. Antiviral capsid-binding compounds can inhibit the adsorption of minor receptor rhinoviruses.
Dewindt B; van Eemeren K; Andries K
Antiviral Res; 1994 Sep; 25(1):67-72. PubMed ID: 7811059
[TBL] [Abstract][Full Text] [Related]
3. Antivirus agent, Ro 09-0410, binds to rhinovirus specifically and stabilizes the virus conformation.
Ninomiya Y; Ohsawa C; Aoyama M; Umeda I; Suhara Y; Ishitsuka H
Virology; 1984 Apr; 134(2):269-76. PubMed ID: 6100571
[TBL] [Abstract][Full Text] [Related]
4. Binding affinities of structurally related human rhinovirus capsid-binding compounds are related to their activities against human rhinovirus type 14.
Fox MP; McKinlay MA; Diana GD; Dutko FJ
Antimicrob Agents Chemother; 1991 Jun; 35(6):1040-7. PubMed ID: 1656851
[TBL] [Abstract][Full Text] [Related]
5. Antigenic determinants of infective and inactivated human rhinovirus type 2.
Lonberg-Holm K; Yin FH
J Virol; 1973 Jul; 12(1):114-23. PubMed ID: 4126195
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and activity of piperazine-containing antirhinoviral agents and crystal structure of SDZ 880-061 bound to human rhinovirus 14.
Oren DA; Zhang A; Nesvadba H; Rosenwirth B; Arnold E
J Mol Biol; 1996 May; 259(1):120-34. PubMed ID: 8648640
[TBL] [Abstract][Full Text] [Related]
7. Kinetics of thermal denaturation of human rhinoviruses in the presence of anti-viral capsid binders analyzed by capillary electrophoresis.
Okun VM; Nizet S; Blaas D; Kenndler E
Electrophoresis; 2002 Mar; 23(6):896-902. PubMed ID: 11920874
[TBL] [Abstract][Full Text] [Related]
8. Capillary electrophoresis of affinity complexes between subviral 80S particles of human rhinovirus and monoclonal antibody 2G2.
Kremser L; Petsch M; Blaas D; Kenndler E
Electrophoresis; 2006 Jul; 27(13):2630-7. PubMed ID: 16732623
[TBL] [Abstract][Full Text] [Related]
9. Comparison of in vitro and cell-mediated alteration of a human Rhinovirus and its inhibition by sodium dodecyl sulfate.
Lonberg-Holm K; Noble-Harvey J
J Virol; 1973 Oct; 12(4):819-26. PubMed ID: 4359954
[TBL] [Abstract][Full Text] [Related]
10. VP1 sequencing of all human rhinovirus serotypes: insights into genus phylogeny and susceptibility to antiviral capsid-binding compounds.
Ledford RM; Patel NR; Demenczuk TM; Watanyar A; Herbertz T; Collett MS; Pevear DC
J Virol; 2004 Apr; 78(7):3663-74. PubMed ID: 15016887
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and evaluation of novel chloropyridazine derivatives as potent human rhinovirus (HRV) capsid-binding inhibitors.
Fan SY; Zheng ZB; Mi CL; Zhou XB; Yan H; Gong ZH; Li S
Bioorg Med Chem; 2009 Jan; 17(2):621-4. PubMed ID: 19091578
[TBL] [Abstract][Full Text] [Related]
12. Lack of quantitative correlation between inhibition of replication of rhinoviruses by an antiviral drug and their stabilization.
Andries K; Dewindt B; Snoeks J; Willebrords R
Arch Virol; 1989; 106(1-2):51-61. PubMed ID: 2548460
[TBL] [Abstract][Full Text] [Related]
13. Conformational change in the floor of the human rhinovirus canyon blocks adsorption to HeLa cell receptors.
Pevear DC; Fancher MJ; Felock PJ; Rossmann MG; Miller MS; Diana G; Treasurywala AM; McKinlay MA; Dutko FJ
J Virol; 1989 May; 63(5):2002-7. PubMed ID: 2539499
[TBL] [Abstract][Full Text] [Related]
14. Nonneutralizing human rhinovirus serotype 2-specific monoclonal antibody 2G2 attaches to the region that undergoes the most dramatic changes upon release of the viral RNA.
Hewat EA; Blaas D
J Virol; 2006 Dec; 80(24):12398-401. PubMed ID: 17005641
[TBL] [Abstract][Full Text] [Related]
15. Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders.
Morley A; Tomkinson N; Cook A; MacDonald C; Weaver R; King S; Jenkinson L; Unitt J; McCrae C; Phillips T
Bioorg Med Chem Lett; 2011 Oct; 21(20):6031-5. PubMed ID: 21907579
[TBL] [Abstract][Full Text] [Related]
16. Molecular Determinants of Human Rhinovirus Infection, Assembly, and Conformational Stability at Capsid Protein Interfaces.
Valiente L; López-Argüello S; Rodríguez-Huete A; Valbuena A; Mateu MG
J Virol; 2022 Dec; 96(23):e0084022. PubMed ID: 36374110
[TBL] [Abstract][Full Text] [Related]
17. Formation of rhinovirus-soluble ICAM-1 complexes and conformational changes in the virion.
Hoover-Litty H; Greve JM
J Virol; 1993 Jan; 67(1):390-7. PubMed ID: 8093221
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity.
Barnard DL; Hubbard VD; Smee DF; Sidwell RW; Watson KG; Tucker SP; Reece PA
Antimicrob Agents Chemother; 2004 May; 48(5):1766-72. PubMed ID: 15105133
[TBL] [Abstract][Full Text] [Related]
19. Antiviral effect of hyperthermic treatment in rhinovirus infection.
Conti C; De Marco A; Mastromarino P; Tomao P; Santoro MG
Antimicrob Agents Chemother; 1999 Apr; 43(4):822-9. PubMed ID: 10103186
[TBL] [Abstract][Full Text] [Related]
20. Characterization of rhinovirus subviral A particles via capillary electrophoresis, electron microscopy and gas phase electrophoretic mobility molecular analysis: part II.
Subirats X; Weiss VU; Gösler I; Puls C; Limbeck A; Allmaier G; Kenndler E
Electrophoresis; 2013 Jun; 34(11):1600-9. PubMed ID: 23483563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
